Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Nathan, Robison"'
Autor:
Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave, AeRang Kim, Laura J Klesse, Mignon Loh, Staci Martin, Christopher Moertel, Roger Packer, Jonathan M Payne, Katherine A Rauen, Jonathan J Rios, Nathan Robison, Elizabeth K Schorry, Kevin Shannon, David A Stevenson, Elliot Stieglitz, Nicole J Ullrich, Karin S Walsh, Brian D Weiss, Pamela L Wolters, Kaleb Yohay, Marielle E Yohe, Brigitte C Widemann, Michael J Fisher
Publikováno v:
Neuro Oncol
Neuro-Oncology, vol 24, iss 11
Neuro-Oncology, vol 24, iss 11
The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1 (NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase kinase inhibitors (MEKi) block downstream targets of RAS. The recent
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
PDF file 92K, Supplemental Fig 5: Expression of PID1 protein in human brain tumors and cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d82bea2b8c767c454086e43a6cb428cd
https://doi.org/10.1158/1078-0432.22449965
https://doi.org/10.1158/1078-0432.22449965
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
PDF file - 190K, Supplemental Fig 2: Proneural and Neural GBMs have higher PID1 mRNA; higher PID1 mRNA correlates with higher OS in patients with gliomas.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc273645c3c2cb62aa3119bfff91078
https://doi.org/10.1158/1078-0432.22449974.v1
https://doi.org/10.1158/1078-0432.22449974.v1
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
PDF file - 159K, Supplemental Fig 1: PID1 mRNA is lower in less favorable medulloblastomas in two additional independent datasets; PID1 mRNA correlates with rf-PFS when analyzing CHLA medulloblastomas by tertiles.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc3d85666d5ca39bff7ed5663e6d04d
https://doi.org/10.1158/1078-0432.22449977.v1
https://doi.org/10.1158/1078-0432.22449977.v1
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
PDF file - 17K, Supplemental Fig 4: PID1 increases the proportion of cells in Sub G0/G1 in CHLA-259 medulloblastoma cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61093f972bcf75092590c405fa1c3215
https://doi.org/10.1158/1078-0432.22449968
https://doi.org/10.1158/1078-0432.22449968
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
Purpose: We present here the first report of PID1 (Phosphotyrosine Interaction Domain containing 1; NYGGF4) in cancer. PID1 was identified in 2006 as a gene that modulates insulin signaling and mitochondrial function in adipocytes and muscle cells.Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c143c3c543fc8e4407e7c83c12e25822
https://doi.org/10.1158/1078-0432.c.6521810
https://doi.org/10.1158/1078-0432.c.6521810
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
PDF file - 440K, Supplemental Table 1: Characteristics of the CHLA Medulloblastoma Patients. Supplemental Table 2: Neural and Proneural GBM subgroups have higher PID1 mRNA compared to Classical and Mesenchymal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a79da4827af21a1d7b7b3d6849de249
https://doi.org/10.1158/1078-0432.22449959.v1
https://doi.org/10.1158/1078-0432.22449959.v1
Autor:
Shahab Asgharazadeh, Richard Sposto, Marcel Kool, Stefan M. Pfister, David T.W. Jones, Alexander R. Judkins, Mark D. Krieger, Ashley S. Margol, Gregory M. Shackleford, Jemily Malvar, Lingyun Ji, Floyd H. Gilles, Mathew Schur, Tom B. Davidson, Jingying Xu, Hong Zhou, Xiuhai Ren, Nathan Robison, Anat Erdreich-Epstein
PDF file - 42K, Supplemental Fig 3: PID1 also inhibits colony formation using two other plasmid expression vectors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f613692d8ddcc5598abc847cc41b84
https://doi.org/10.1158/1078-0432.22449971.v1
https://doi.org/10.1158/1078-0432.22449971.v1
Autor:
Nathan Robison, Giles W. Robinson, Tina Young Poussaint, Lindsay Kilburn, Stewart Goldman, Maryam Fouladi, Adekunle M. Adesina, Sonia Partap, Donald W Parsons, Ian F. Pollack, Ira J. Dunkel, Arzu Onar-Thomas, Catherine A. Billups, Ashok Panigrahy, Regina I. Jakacki, Alberto Broniscer
Publikováno v:
Neuro Oncol
BackgroundCraniopharyngiomas account for approximately 1.2–4% of all CNS tumors. They are typically treated with a combination of surgical resection and focal radiotherapy. Unfortunately, treatment can lead to permanent deleterious effects on behav
Autor:
Peter E. Manley, Nathan Robison, Stewart Goldman, Michael Fisher, John P. Perentesis, Alan B. Cantor, Coretta Thomas, Bruce R. Korf, Alyssa Reddy, Mark W. Kieran, Susan N. Chi, Sanjay P. Prabhu, Nicole J. Ullrich, Tomoyuki Mizuno, Jeffrey C. Allen, Alexander A. Vinks, David Viskochil, Gary Cutter, Roger J. Packer, David H. Gutmann
Publikováno v:
Neuro-oncology, vol 22, iss 10
Neuro Oncol
Neuro Oncol
Background Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in thi